About Neurovance
Neurovance is a company based in Cambridge (United States) founded in 2011 was acquired by Otsuka in March 2017. Neurovance has raised $53.03 million across 6 funding rounds from investors including Otsuka, Tekla Capital Management and Venture Investors. The company has 7 employees. Neurovance operates in a competitive market with competitors including Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others.
- Headquarter Cambridge, United States
- Employees 7
- SectorsHealthcare
- Website neurovance.com
- Acquired by Otsuka (Mar 2017)
Funding Insights of Neurovance
Neurovance has successfully raised a total of $53.03M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $554.28 thousand completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $53.03M
- Total Rounds 6
- Last Round Series B — $554,280
- First Round $478,064
(May 2012)
- Investors Count 5
All 6 funding rounds of Neurovance with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2017 | $554,280 | Series B | – | – | – |
| Dec 2016 | $7.5M | Series B | – | – | – |
| Jun 2015 | $26.5M | Series B | – | – | – |
| Mar 2014 | $10.5M | Series B | – | Venture Investors, GBS | – |
| Oct 2013 | $7.5M | Series A | – | Novartis Venture Fund | |
| May 2012 | $478,064 | Seed | – | GBS, Venture Investors | – |
6 investors in total: 6 institutional.
Investors in Neurovance
Neurovance has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Otsuka, Tekla Capital Management and Venture Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors focused seed & early stage VC firm investing in the US, Europe & Asia | – | ventureinvestors.com | Madison, United States | |
- | – | gbsventures.com.au | - | |
Investments are made in innovative life science companies globally. | – | nvfund.com | Basel, Switzerland | |
Investment advisory services are provided to financial clients. | 1986 | teklacap.com | Boston, United States | |
- | – | swib.state.wi.us | - | |
Generic pharmaceuticals and nutraceuticals are manufactured and marketed by Otsuka. | 1921 | otsuka.com | Chiyoda City, Japan |
Investor details for Neurovance
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Neurovance
130 people are tracked at Neurovance (88 in leadership, 42 in team); the tracked headcount is 7.
| Name | Role | Group |
|---|---|---|
Tarek Rabah | President & CEO, Otsuka North America | Leadership |
Theresa Menders | Chief Of Staff And Senior Director, HR Strategic Programs | Leadership |
Neveen Abou-Gharbia | Executive Director, CNS Marketing Brand Lead (mdd/ptsd) | Leadership |
Tarolyn Carlton | Senior Director, Global Medical Affairs, Digital Medicine & Digital Therapeutics | Leadership |
Zia Haque | Senior Director. Head, Data Management | Leadership |
Shannon Addington | Director Field Strategy And Operations | Leadership |
Wyatt Vrancken | Associate Director, Central Nervous System (cns) Brand & Sales Analytics | Leadership |
Lindsey Bechtel | Director Data Management | Leadership |
Jeff Cochran | Director, Data Scientist | Leadership |
John Kraus | EVP & Chief Medical Officer | Leadership |
Tifani McCann | Vp, Head Of Data & Analytics, Chief Data & Analytics Officer | Leadership |
Abhinandan Raghavan | Director of Real World and Clinical Data Science | Leadership |
Sheenie A. | Senior Director, Global Marketing & Market Access | Leadership |
Soham Shah | Director, Commercial Insights & Analytics | Leadership |
Cara Klose | Director, HR Business Partner | Leadership |
Jin Tong | Director, Forecasting & Commercial Analytics | Leadership |
Louis Allesandrine | VP & Commercial Franchise Head, Nephrology | Leadership |
Junea Williams-Edmund | Director, Corporate Counsel | Leadership |
Chelsea Martino | Director, Compliance Counsel | Leadership |
Steve Rosen | VP & CFO | Leadership |
110 more people are available in the full profile.
Complete people profiles for Neurovance
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Neurovance
4 dated milestones of Neurovance across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Neurovance is founded.
- Funding First funding round of $478K.
- Funding Latest funding round, Series B, of $554K.
- Exit Acquired by Otsuka.
Competitors of Neurovance
Neurovance operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| altoneuroscience.com | 2019 | San Francisco, United States | $144.72M | 34 | AI-driven drug discovery platform for neurological diseases based on patients biomarkers | |
| supernus.com | 2005 | Rockville, United States | – | 652 | Specialty pharmaceutical products for CNS diseases are developed and commercialized. | |
| newron.com | 1999 | Milan, Italy | $54.94M | – | Therapies for central nervous system diseases and pain are developed. | |
| reunionneuro.com | 2022 | Toronto, Canada | $103M | – | Therapeutics for mental health conditions are developed using serotonergic psychedelics. | |
| cerecor.com | 2011 | Baltimore, United States | $45.2M | 20 | Therapeutics for immunological and neurological disorders are developed. | |
| seaporttx.com | 2020 | Boston, United States | $325M | – | Novel therapeutics for neuropsychiatric disorders are developed using proprietary technology. | |
| vandapharma.com | 2003 | – | $33.5M | 203 | Pharmaceutical products for CNS disorders are developed and commercialized. | |
| hmnc-brainhealth.com | 2010 | Munich, Germany | $24.64M | – | Targeted therapies and personalized tests for neuropsychiatric disorders are developed. | |
| evecxia.com | 2013 | Durham, United States | $14.85M | – | Therapies for CNS disorders are developed by Evecxia Therapeutics. |
Detailed competitors of Neurovance
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neurovance
Complete news archive for Neurovance
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Neurovance
10 companies that operate in the same segment as Neurovance (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Neurovance
Neurovance was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Neurovance is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Neurovance is a funded company, having raised a total of $53.03M across 6 funding rounds to date. The company's 1st funding round was a Seed of $478.06K, raised on May 2012.
Neurovance has 7 employees.
Neurovance was established in 2011 in Cambridge, United States, as a clinical-stage company in the neuroscience sector. Centanafadine, a triple reuptake inhibitor targeting norepinephrine, dopamine, and serotonin, is advanced for adult ADHD management. An extended-release formulation of this compound is under development for adolescent and pediatric ADHD to support improvements in attention and executive function.
Neurovance's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Newron Pharmaceuticals.
Neurovance has 6 investors. Key investors include Otsuka, Tekla Capital Management, Venture Investors, GBS, and Novartis Venture Fund.
Yes. Neurovance was acquired by Otsuka in March 2017.